Evidence map›Paper›PMID 34921673›Full record

ReviewFrontiers of medicine2021

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Jian-Qing Mi, Jie Xu, Jianfeng Zhou, Weili Zhao, Zhu Chen, J Joseph Melenhorst, Saijuan Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Frontiers of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Emerging Roles of Fc Receptor-Like 1 in Immunotherapy of Diffuse Large B-Cell Lymphoma.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2025
    Article
  3. Review
  4. Review
  5. Nitazoxanide and COVID-19: A review.Molecular biology reports · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jian-Qing MiState Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jie XuState Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jianfeng ZhouImmunotherapy Research Centre for Hematologic Diseases of Hubei Province, Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Weili ZhaoState Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Zhu ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
J Joseph MelenhorstDepartment of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. jos.melenhorst@pennmedicine.upenn.edu.
Saijuan ChenState Key Laboratory of Medical Genomics, Shanghai Institute of Haematology, National Research Centre for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. sjchen@stn.sh.cn.
Ruijin Hospital · CNShanghai Jiao Tong University · CNTongji Hospital · CNUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.

Indexed as

Hematologic NeoplasmsNeoplasmsReceptors, Chimeric AntigenHumansImmunotherapyT-LymphocytesReceptors, Chimeric AntigenCAR T cellshematological malignanciesreview

Identifiers

PMID34921673
OpenAlexW4200105108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.